We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bonito Peptides (Katsuobushi Oligopeptide / Val-Tyr)
Short ACE-inhibitory peptides from enzyme-digested dried bonito (Katsuobushi) fish muscle — notably the dipeptide Val-Tyr ("VY") and the prodrug-type pentapeptide LKPNM — sold as a food-derived supplement for blood pressure. Honest appraisal: a handful of small, mostly Japanese, often industry-linked RCTs show a modest blood-pressure drop in people with mild/high-normal hypertension, on the same ACE-inhibition mechanism as related fish/sardine and milk (lactotripeptide) peptides. The effect is small, the trials are small, and benefit concentrates in (pre)hypertensive people — not normotensives.
What the evidence says
Most Bonito Peptides studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1992–2020 with a typical study size of 29 participants.
Based on 12 studies · 5 RCTs · 128 total participants
Confidence
ModerateBy outcome
Bonito Peptides has an evidence score of 3.5/10 — emerging evidence based on 12 indexed studies. Short ACE-inhibitory peptides from enzyme-digested dried bonito (Katsuobushi) fish muscle — notably the dipeptide Val-Tyr ("VY") and the prodrug-type pentapeptide LKPNM — sold as a food-derived supplement for blood pressure. Honest appraisal: a handful of small, mostly Japanese, often industry-linked RCTs show a modest blood-pressure drop in people with mild/high-normal hypertension, on the same ACE-inhibition mechanism as related fish/sardine and milk (lactotripeptide) peptides. The effect is small, the trials are small, and benefit concentrates in (pre)hypertensive people — not normotensives. Representative study: PMID 10962520.
The commonly studied dose of Bonito Peptides is Trials used ~1.5-3 mg Val-Tyr/day (e.g. a 3 mg VY drink, twice daily), or labeled katsuobushi-oligopeptide products providing the equivalent; follow product labeling. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Glycomacropeptide
Mostly mechanism / observationalA 64-amino-acid peptide released from kappa-casein during cheese-making, sold both as a whey-derived satiety supplement and (amino-acid-fortified) as a low-phenylalanine protein for PKU. Honest appraisal: the appetite/satiety evidence is genuinely mixed — several acute RCTs found NO effect of GMP itself on CCK, satiety ratings, or food intake, while a few found small reductions in energy intake. Its established, evidence-supported use is as a near-phenylalanine-free protein substitute in phenylketonuria, where it works as well as (not clearly better than) amino-acid formulas.
Explore: Best supplements for Vitality & Longevity
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Scores low-moderate/Emerging because a few small, short, mostly Japanese and often industry-affiliated RCTs show only a modest blood-pressure drop in (pre)hypertensives, with no meta-analyses and a plausible ACE-inhibition mechanism.
Bonito peptides are short peptides released when dried bonito (Katsuobushi, a Japanese fish seasoning) muscle protein is digested with enzymes such as thermolysin.
The mixture (a "katsuobushi oligopeptide") contains several angiotensin-I-converting-enzyme (ACE) inhibitory peptides isolated from the digest — the dipeptide Val-Tyr ("VY", also derivable from sardine muscle) and the pentapeptide Leu-Lys-Pro-Asn-Met (LKPNM) are the most studied.
LKPNM is a "prodrug-type" inhibitor: it is itself a weak ACE inhibitor but is cleaved by ACE to LKP, an ~8-fold more potent inhibitor, giving a delayed, prolonged effect.
Mechanistically this is the same renin-angiotensin-system target as ACE-inhibitor drugs and as milk-derived lactotripeptides (VPP/IPP) — but the food peptides are far weaker. The honest human evidence is thin and modest.
The clearest signal comes from small Japanese double-blind RCTs in mild/high-normal hypertension: a Val-Tyr/sardine drink lowered systolic BP by roughly 9 mmHg and diastolic by ~5 mmHg over 4 weeks in one ~29-person trial, and a sardine-peptide vegetable drink lowered SBP ~7-8 mmHg in another.
Dried-bonito-broth crossover studies in elderly subjects show smaller SBP reductions (and a fall in the oxidative-stress marker 8-OHdG). Against this, human pharmacokinetic work shows Val-Tyr is absorbed intact but did NOT produce an acute BP change at the doses tested, and effects in older/aged animals are blunted.
The trials are small, short, geographically narrow, frequently funded by or affiliated with the manufacturers, and prone to publication bias — exactly the pattern seen across food-derived ACE-inhibitory peptides.
Treat this as a modest, food-grade lifestyle adjunct for blood pressure, not a substitute for antihypertensive medication. Overall evidence is emerging/low-moderate.
Bonito-derived peptides (Val-Tyr, LKPNM and others) competitively inhibit angiotensin-I-converting enzyme in vitro — the same renin-angiotensin-system target as ACE-inhibitor drugs, reducing formation of the vasoconstrictor angiotensin II.
LKPNM is a weak inhibitor that ACE itself cleaves to LKP, an ~8-fold more potent ACE inhibitor — giving a delayed, prolonged blood-pressure effect after oral intake in animal models.
Beyond ACE inhibition, related peptides (Val-Tyr, sardine Met-Tyr) show antiproliferative effects on vascular smooth muscle and endothelial antioxidant induction in cell models, and human broth studies report lower oxidative-stress markers — proposed but not established contributors.
How Bonito Peptides works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Trials used ~1.5-3 mg Val-Tyr/day (e.g. a 3 mg VY drink, twice daily), or labeled katsuobushi-oligopeptide products providing the equivalent; follow product labeling
Take with food
| Form | Type |
|---|---|
| 💊Katsuobushi oligopeptide (Val-Tyr-standardized) drink or capsule | Recommended |
| 💊Sardine peptide (Val-Tyr) preparations | Alternative |
| 💊Milk lactotripeptides (VPP/IPP) — same ACE-inhibition rationale | Alternative |
Bonito, sardine, and milk lactotripeptide products share the ACE-inhibitory mechanism and the same modest, heterogeneous blood-pressure evidence.
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Consistent daily intake; effect builds over 1-4 weeks and reverses when stopped.
Dose-response data unavailable. The current published research for Bonito Peptides does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Small SBP/DBP reductions in mild/high-normal hypertension in short Japanese RCTs.
Benefit concentrates in (pre)hypertensive people; normotensive subjects show little change, and one human PK study found no acute BP change despite absorption.
Food-derived; trials reported no abnormal hematology, blood chemistry, or urinalysis changes. Fish allergy is the main contraindication.
Avoid — the peptides are derived from fish muscle.
Safe as a food, but monitor blood pressure for additive lowering and discuss with a clinician.
Likely safe as a food-derived peptide at culinary/labeled doses; not specifically studied — choose mercury-low, well-sourced products and consult a clinician.
Same renin-angiotensin-system target; theoretical additive blood-pressure lowering. The effect of the peptides is small, but monitor BP if combining.
ACE-inhibitor-class mechanisms can raise potassium; additive risk is theoretical and minor at food-peptide doses, but relevant with prescription RAAS drugs.
Tip: Trials reported no abnormal hematology, blood chemistry, urinalysis, heart rate, or weight changes.
Tip: Avoid if allergic to fish/bonito/sardine.
Timing is flexible for Bonito Peptides — consistent daily use matters more than the time of day. Studied as a daily drink or capsule; the prodrug-type peptides act on a delayed timescale, so consistent daily intake matters more than time of day.
Bonito Peptides is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are none notable in trials, allergic reaction (fish-allergic individuals). Use caution if any of these apply to you: Fish allergy (bonito/sardine-derived); Caution if already on ACE-inhibitor / antihypertensive medication (theoretical additive blood-pressure lowering).
Lactotripeptides
Mostly mechanism / observationalTwo milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT).